tbuckley/cabot-search huggingface dataset:
AB0744 There is NO Relationship between Glucagon like Peptide-1 and Inflammation in Psoriasis and Psoriatic Arthritis: Table 1.
Authors: M. Keser, P. Cetin, D. Solmaz, D. Kozacı, N. Gunay, S. Oztürk, I. Sarı, S. Akar, M. Birlik, N. Akkoc, F. Onen
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Several studies have found a higher prevalence of type 2 diabetes mellitus in patients with psoriasis and psoriatic arthritis (PsA). Interestingly, a complete remission of psoriasis has been observed following immediately after the gastric bypass surgery in obese diabetic patients before any weight loss could have occurred, most likely due to the increased levels of GLP-1. There have been also diabetic cases who have showed improvements in psoriasis under the treatment with GLP-1 receptor agonists and with dipeptidyl peptidase-IV (DPP-IV) inhibitors.GLP-1 was suggested to have anti-inflammatory effects in addition to its effects on glucose homeostasis. <h3>Objectives</h3> To investigate the GLP-1 level and its relationship with inflammation in patients with psoriasis and PsA. <h3>Methods</h3> This study included non-diabetic PsA patients and healthy controls. Disease activity was assessed in the patients by using “Composite Psoriatic Disease Activity Index (CPDAI)” which assessed five domains of disease: peripheral arthritis, dactylitis, enthesitis, axial involvement and skin findings. High-sensitive C-reactive protein (hs-CRP) levels were also investigated for the assessment of the disease activity. Fasting blood GLP-1 levels were measured in PsA patients by using ELISA method and compared with those measured in the controls. <h3>Results</h3> There were 97 PsA patients who fulfilled the CASPAR criteria. Fifty-seven healthy sex, age- and –body mass index (BMI) matched hospital workers were evaluated as controls (Table 1).14 patients had predominantly axial and 52 had predominantly peripheral disease. 22 (17.5%) were receiving corticosteroids. 12 patients (7.8%) were on anti-TNF treatment, 78 (%80.4) were on methotrexate.There was no statistically significant difference in the GLP-1 levels between PsA patients and healthy controls. GLP-1 levels in patients with active disease were also not different from inactive patients and controls. No difference was determined in GLP-1 levels between patients with predominantly axial and predominantly peripheral disease and healthy controls. GLP-1 levels in patients with psoriasis and PsA were not correlated with the other disease activity scores including BASDAI, DAS28, PASI and hsCRP levels. There was also no correlation between GLP-1 level and functional disease index (BASFI) and also health assessment parameters (HAQ, ASQoL). The subgroup analysis in patients who were not taking glucocorticoid treatment (n:27) revealed the similar results. <h3>Conclusions</h3> The results of this study suggests that there is no significant relationship between GLP-1 and inflammatory process in patients with psoriasis and PsA. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4514
UK will be groundbreaker if proposed regulations for mitochondrial donation are adopted, MPs hear
Authors: A. O'Dowd
Journal: BMJ (2014)

<h3>Objective:</h3> We sought to identify pretreatment neuroimaging markers associated with intracerebral hemorrhage (ICH) after reperfusion therapy for acute ischemic stroke. <h3>Methods:</h3> A literature review using available online medical literature databases was performed to identify noninvasive imaging markers correlated with ICH after reperfusion therapy. Key words, including different neuroimaging modalities such as noncontrast CT, multimodal CT, and MRI techniques, were queried. The review included randomized, controlled trials, post hoc studies, and institutional registries. Studies of IV as well as intra-arterial reperfusion therapies were considered. Articles were organized on the basis of imaging modality and type of treatment. Each imaging modality was given 1 of 3 grades for consideration of use in clinical practice (grade 1: a modality whose use for hemorrhage prediction is supported by randomized controlled trials or post hoc studies from prospective trials; grade 2: a modality that is largely available but requires further prospective validation; and grade 3: a modality which is rarely used and has limited clinical utility). <h3>Results:</h3> Grade 1 imaging modalities included the size of infarction as seen on noncontrast CT or diffusion MRI. Higher hemorrhagic risk has been seen with larger infarctions, suggesting that these imaging modalities may be effective screening tests to exclude specific patients. Perfusion imaging using CT or MRI was considered to have a grade 2 recommendation, pending further validation. The use of xenon CT, radionuclide imaging, voxel-based MRI analysis, and blood–brain barrier disruption imaging still require further design improvements (grade 3). <h3>Conclusions:</h3> Future reperfusion trials require clearly defined protocols for imaging and determination of symptomatic ICH. Future trials may consider the use of perfusion imaging and the inclusion of patients without large territorial infarctions to accurately predict those at risk for ICH with reperfusion therapy.
Ectopic Ovary and Unicornuate Uterus
Authors: Willem Ombelet, Geert Verswijvel, Eric de Jonge
Journal: New England Journal of Medicine (2003)

To the Editor: Ectopic ovaries are characterized by their attachment to an area above the level of the common iliac vessels.1 Although they may occur in women with a normal uterus, the incidence is reported to be as high as 20 percent when the uterus is absent and 42 percent in cases of a unicornuate uterus.2 Despite the well-known association of ectopic ovaries and a unicornuate uterus, ectopic ovaries are reported only sporadically, suggesting the possibility that many cases go unrecognized.3–5 We report two cases in which an ectopic ovary was detected in association with a unicornuate uterus. A . . .
P577Relationship between rs1805124 polymorphism of SCN5A gene and primary left bundle branch block:
Authors: A Chernova, S YU Nikulina
Journal: Cardiovascular Research (2014)

Background: Progressive left bundle branch block (LBBB) is a hereditary arrhythmia characterized by progressive conduction disturbances in the His-Purkinje system. LBBB has been linked to genes such as SCN5A that influence cardiac excitability but not to genes that influence cell-to-cell communication. Our goal was to explore whether nucleotide substitutions in genes coding SCN5A for cardiac channels would associate with LBBB. Material and Methods: A family examination was performed in 96 patients with primary left bundle branch block (LBBB). The control group consisted of 411 patients without clinical ECG manifestations of cardiac diseases. All the examinees have undergone ECG, echocardioscopy, electrophysiological examination of the heart. Results: by results of research it is established that the frequency of carriers of a heterozygous genotype (AG) among patients with LBBB (50%±5,1) was higher in comparison with control selection (34,8%±2,3). The obvious tendency to decrease in carriers of a homozygous genotype on extended allel (AA) among patients with LBBB (50%±5,1) in comparison with group of control (61,6%±2,4) is also noted. Conclusions: In this work we for the first time revealed on clinical - genetic material association between hereditary disturbances of cardiac conduction, such as LBBB and rs1805124 polymorphism of SCN5A gene.
Abstract 3190: Inhibition of the translation of A-myb mRNA by tumor suppressor protein Pdcd4.
Authors: Abhiruchi Biyanee, Karl-Heinz Klempnauer
Journal: Cancer Research (2013)

Abstract Pdcd4 (Programmed cell death protein 4) was first identified as a protein to be expressed during apoptosis. Later it was shown that Pdcd4 acts as a tumor suppressor protein and regulates the cellular processes on various levels, encompassing transcription and translation. Pdcd4 interacts with the translation initiation factor eIF4A and inhibits its helicase activity which is required to unwind secondary structures in the 5’UTRs of mRNAs. Previous studies on artificial mRNAs have revealed that it inhibits the translation of mRNAs with secondary structures in their 5’ UTRs. Recently, c-myb mRNA was identified as a natural target RNA of Pdcd4. A-myb is a member of the myb family which is expressed in certain hematopoietic cells, such as B-cells, but also in certain non-hematopoietic cells. We have observed that Pdcd4 inhibits the translation of A-myb mRNA in co-transfection experiments using Pdcd4 expression vectors as well as on the endogenous level, as demonstrated by the analysis of a Pdcd4 knock-out model in the Chicken B-cell line DT40. We found that a mutant of Pdcd4 which no longer interacts with eIF4 is still able to inbihit the translation of A-myb RNA, suggesting that Pdcd4 acts in an eIF4A independent manner and contradicting the current view of how Pdcd4 suppresses translation. Similar to the situation in the case of c-myb RNA we have localized the Pdcd4 responsive region in the coding region of A-myb mRNA. We therefore conclude that Pdcd4 suppresses the translation of A-myb RNA by a novel mechanism. Ribosome density profiling technique is widely used nowadays to explore the topography of the various stages of translation. Currently we aim to exploit the technique of ribosome density profiling to further understand how Pdcd4 affects the translation of A-myb RNA. Citation Format: Abhiruchi Biyanee, Karl-Heinz Klempnauer. Inhibition of the translation of A-myb mRNA by tumor suppressor protein Pdcd4. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3190. doi:10.1158/1538-7445.AM2013-3190
DIGOXIN USE IN ATRIAL FIBRILLATION IS ASSOCIATED WITH INCREASED RISK OF MORTALITY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF MORE THAN 200,000 PATIENTS
Authors: Waqas Qureshi, Zaid Alirhayim, Amjad Ahmed, Mouaz Al-Mallah, King AbdulAziz
Journal: Journal of the American College of Cardiology (2015)
Abstract P3-12-06: Clinicopathological Analysis of Breast Cancer Patients with Brain Metastases
Authors: A Ushio, M Sawaki, T Fujita, M Hattori, N Kondo, A Horio, N Gondou, H Iwata
Journal: Cancer Research (2012)

Abstract Background: Recent advances in chemotherapy have enabled to control the progression of metastases from breast cancer except for the brain, highlighting the symptoms associated with brain metastases. In addition, improvement in our understanding of breast cancer biology changed the treatment strategy, possibly leading to improved outcomes in patients with breast cancer and brain metastases. Object: The aim of this study was to investigate the correlation between biology of primary tumors and prognosis of patients with breast cancer metastasis to the brain. Patients and method: Among 3,171 patients with primary breast cancer undergoing surgery at out hospital from 2003 to 2010, 35 patients (1.1%) who developed brain metastases, excluding stage IV at the initial diagnosis. We reviewed 35 patients for a correlation between survival and clinicopathological variables, including stage, hormonal sensitivity, HER2 expression status, the number of brain metastases, and treatment for brain metastases. Results: The mean age of 35 patients was 52.1 years (range 22–68) and the median follow-up period was 41.0 months. The subtypes of primary tumors included triple-negative (TN) in 14 patients (40%), luminal in 11 patients (31.4%), luminal HER2-positive (luminal HER2) in 2 patients (5.7%), and HER2-positive (HER2) in 2 patients (5.7%). The duration from surgery to recurrence (disease-free survival, DFS, months) was 14.7 in TN, 26.5 in luminal, 29.8 in luminal HER2, and 31.0 in HER2. The duration from the first recurrence to the detection of brain metastases (months) was 7.2 in TN, 14.4 in luminal, 15.8 in luminal HER2, and 4.0 in HER2. The mean survival time after the diagnosis of brain metastases was 8.6 months (range, 0–40) with a survival time of ³ 1 year in 8/35 patients (23%) and that of &amp;lt; 1 year in 21/35 patients (60%). Both DFS and the duration from the first recurrence to the diagnosis of brain metastases were shorter in TN compared with other subtypes. In HER2 subtype, DFS was long but, once recurrence was detected, the duration to the development of brain metastases was short. In multivariate analysis of clinicopathological variables (age, DFS, ER, HG, HER2, the number of brain metastases (solitary versus multiple), the site of initial metastasis (brain versus other organs), and the presence or absence of chemotherapy after brain metastases, revealed solitary brain metastasis (p = 0.002) and the initial metastatic site of brain (p = 0.003) to be independent factors predicting survival. Conclusion: The clinical outcomes of brain metastases were different among tumor subtypes. Factors predicting survival in patients with breast cancer and brain metastases may be the site of initial metastasis, the number of brain metastasis, and local treatment for brain metastases. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-12-06.
AB0857 Single nucleotide polymorphisms associated with non response to anti-TNF-alpha treatment in ankylosing spondylitis patients. Data from regisponser:
Authors: R. Schiotis, A. Sánchez, N. Bartolomé, M. Szczypiorska, J. Sanz, A. Martínez, D. Tejedor, M. Artieda, J. Mulero, P. Font, A. Escudero, A. Buzoianu, D. Macarie, E. Collantes
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Taking into account that almost 40% of AS patients remain disease active even on long term biological treatment<sup>1</sup>, genetic biomarkers that differentiate between responders and non-responders would be useful in selecting the apropiate treatment. <h3>Objectives</h3> The aim of the study was to investigate candidate single nucleotide polymorphisms (SNPs) responsible for non response to TNF-alpha blockers in Spanish AS patients at the beginning of the first anti- TNF-alpha agent. <h3>Methods</h3> We undertook an association study on AS patients enrolled in the REGISPONSER. The patients were classified as “non-responders” if they failed to achieve BASDAI50 improvement criteria at the visit that followed treatment initiation. We selected candidate SNPs which were previously described as associated with susceptibility or pathogenesis of AS and/or other spondylartropathies. SNP genotyping was performed using the Illumina Golden gate genotyping platform. Statistical analysis was performed with the SPSS v19.0 and the SVS v7.3.1 softwares.P-values of &lt;0,05 were considered statistically significant. <h3>Results</h3> Among 121 patients who fulfilled the inclusion criteria, 68 (56.2%) were responders and 53(43.8%) were non-responders.The mean age of studied patients was 47.7 years (±9.5), with mean disease duration since first symptoms of 21.1 years (±8.9). There were no significant differences in baseline clinical and demographic characteristics in the two treatment response groups. From the 345 SNPs tested for association with treatment response status, 10 polymorphisms remained associated after adjustment for multiple testing. Risk alleles of SNPs associated with non-response to anti-TNF-alpha treatment by their OR with 95% confidence intervals (CI) are listed in table 1. <h3>Conclusions</h3> Our study identified 10 different polymorphisms in 10 different genes associated with non response to TNF-alpha blockers. Validation of these markers in further cohorts would be of great interest to confirm the robustness of our results. <h3>References</h3> Baraliakos X, Listing J, Fritz C, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years – early clinical response predicts long-term outcome. J. Rheumatology (Oxford). 2011 Sep;50(9):1690-9. <h3>Disclosure of Interest</h3> None Declared
Abstract 1625: Discovery of a breast cancer targeting peptide with anti-tumor activity
Authors: Bettina Proneth, Wouter H. Driessen, Amin Hajitou, Fernanda I. Staquicini, Wadih Arap, Renata Pasqualini
Journal: Cancer Research (2010)

Abstract The American Cancer Society estimates 192,370 women will be diagnosed with breast cancer in the United States in 2009, and approximately 40,170 will die of this disease. Towards identifying new ligand-directed therapies for breast cancer, we have developed an in vivo screening method, where peptides that home specifically to the vascular component of tissues are selected after intravenous administration of an engineered combinatorial peptide phage library. We have used this technology for the identification of a new breast cancer targeting peptide and its receptor in a mouse model of highly aggressive and vascularized breast cancer. A random phage library displaying the cyclic sequence CX7C (X = any of the 20 natural amino acids) was injected intravenously in tumor-bearing mice after which phage was recovered from the tumor-tissue by bacterial infection and re-injected for a subsequent round of biopanning. After sequencing of the recovered phage from round 2 and 3 several candidate peptides were identified. One breast cancer targeting peptide (BCTP) was recovered from all tumors with the highest frequency. This peptide showed marked tumor homing as verified by immunohistochemistry (IHC). We used peptide affinity chromatography and tandem mass spectrometry (MS/MS) to identify the target receptor of BCTP. Strikingly, this newly discovered receptor plays an as yet unrecognized role in the pathology of breast cancer. BCPT exhibited strong binding to its receptor as verified by ELISA. To investigate if the BCTP receptor is a relevant candidate drug target in breast cancer, we obtained biopsy samples of breast cancer patients prior to chemotherapy. Strong immunoreactivity of the BCTP receptor was observed in the paraffin embedded tissue sections. Next, mammary tumor-bearing mice were injected twice per week with BCTP, control peptide or saline, systemically. BCTP treated mice demonstrated a marked decrease in tumor size of treated mice, compared to mice injected with PBS alone. We have identified, characterized and validated the peptide BCTP, specifically homing to highly aggressive, vascularized breast tumors. In addition to its tumor targeting capabilities this peptide possesses anti-tumor function in itself, inhibiting tumor growth and progression in tumor-bearing mice. More importantly, the target receptor expression has been verified in human biopsy samples of breast cancer, indicating that this protein might be a promising new drug target. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 1625.
AB0801 Implications of Vitamin D Deficiency for Patients with Ostearthritis
Authors: V. Povoroznyuk, N. Balatska, V. Muts
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> The existence of certain interdependencies between vitamin D status and osteoarthritis (OA) has been known for over 20 years. This issue needs closer investigation, however, as the VDD ramifications are multiple and poorly defined. <h3>Objectives</h3> Establishment of: 1. frequency of vitamin D deficiency (VDD) within the population of OA patients. 2. relationship between VDD and severity of OA, BMD, and well-being for these patients (including quality of life) 3. impact of other factors on the above parameters. <h3>Methods</h3> 83 non-osteoporotic subjects (aged 50–65 years) were enrolled in the study. 85.5% of these were women. All subjects underwent ultrasound densitometry. Numerous questionnaires were also being completed (VAS, Lequesne index, EuroQoL). Blood sampling with subsequent 25(OH)D assessment was done. DXA was utilized to verify BMD. <h3>Results</h3> VDD was found in 79.5% of the subjects. Vitamin D insufficiency was diagnosed in 16.9%. Severity of pain in non-deficient patients was 22.4±8.1 by VAS, whereas vitamin D-deficient subjects were found to have significantly more prominent pain syndrome (57.8±11.8), p&lt;0.05. Quality of life in non-deficient patients as confirmed by EuroQoL-5D was better (3.17±0.91) than in patients with insufficiency (5.05±0.39) and deficiency (5.69±0.54), p&lt;0.05. In addition, 25(OH)D was proven to be linked to PTH level in this patient population. A probable (p&lt;0.05) inverse relationship between BMD in Ward9s area and 25(OH)D level was discovered. <h3>Conclusions</h3> It was proven that VDD frequency and severity among the OA population is significantly higher than that within the reference population. Specifically, severe VDD was registered almost three times as often (39.8%) within the study subjects. On the contrary, no correlation was found between 25(OH)D and X-ray evidence of OA. BMD values in Ward zone may help in identification of vitamin D deficient subjects with OA. Vitamin D level was found out to be closely linked with subjective signs in these patients, thus having an impact on the quality of their life. Further, among this population of the patients VAS turned out to be more predictable and accurate tool compared to Lequesne index. Based upon the study results, routine screening for and correction of VDD may prove to be beneficial for the OA patients. Supplementary therapy with vitamin D preparations was suggested to be an integral part of the treatment of the patients with osteoarthritis, notably since the implementation of this approach is relatively quick and simple. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4903